387 related articles for article (PubMed ID: 19774546)
1. Ifosfamide metabolite chloroacetaldehyde inhibits cell proliferation and glucose metabolism without decreasing cellular ATP content in human breast cancer cells MCF-7.
Knouzy B; Dubourg L; Baverel G; Michoudet C
J Appl Toxicol; 2010 Apr; 30(3):204-11. PubMed ID: 19774546
[TBL] [Abstract][Full Text] [Related]
2. Ifosfamide cytotoxicity on human tumor and renal cells: role of chloroacetaldehyde in comparison to 4-hydroxyifosfamide.
Brüggemann SK; Kisro J; Wagner T
Cancer Res; 1997 Jul; 57(13):2676-80. PubMed ID: 9205076
[TBL] [Abstract][Full Text] [Related]
3. Chloroacetaldehyde: mode of antitumor action of the ifosfamide metabolite.
Brüggemann SK; Radike K; Braasch K; Hinrichs J; Kisro J; Hagenah W; Peters SO; Wagner T
Cancer Chemother Pharmacol; 2006 Feb; 57(3):349-56. PubMed ID: 16133533
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo.
Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T
Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637
[TBL] [Abstract][Full Text] [Related]
5. Glucose-dependent active ATP depletion by koningic acid kills high-glycolytic cells.
Kumagai S; Narasaki R; Hasumi K
Biochem Biophys Res Commun; 2008 Jan; 365(2):362-8. PubMed ID: 17997978
[TBL] [Abstract][Full Text] [Related]
6. Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy.
Benesic A; Schwerdt G; Freudinger R; Mildenberger S; Groezinger F; Wollny B; Kirchhoff A; Gekle M
Kidney Blood Press Res; 2006; 29(5):280-93. PubMed ID: 17035713
[TBL] [Abstract][Full Text] [Related]
7. Targets of chloroacetaldehyde-induced nephrotoxicity.
Knouzy B; Dubourg L; Baverel G; Michoudet C
Toxicol In Vitro; 2010 Feb; 24(1):99-107. PubMed ID: 19733226
[TBL] [Abstract][Full Text] [Related]
8. Necrotic pathway in human osteosarcoma Saos-2 cell death induced by chloroacetaldehyde.
Takahashi K; Sakurai K; Takahashi K; Tanaka H; Fujimoto Y
Anticancer Drugs; 2007 Jun; 18(5):543-53. PubMed ID: 17414623
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of the ifosfamide-induced inhibition of endocytosis in the rat proximal kidney tubule.
Yaseen Z; Michoudet C; Baverel G; Dubourg L
Arch Toxicol; 2008 Sep; 82(9):607-14. PubMed ID: 18214444
[TBL] [Abstract][Full Text] [Related]
10. Combination of imatinib and clotrimazole enhances cell growth inhibition in T47D breast cancer cells.
Motawi TM; Sadik NA; Fahim SA; Shouman SA
Chem Biol Interact; 2015 May; 233():147-56. PubMed ID: 25863232
[TBL] [Abstract][Full Text] [Related]
11. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
12. Control of cellular proliferation by modulation of oxidative phosphorylation in human and rodent fast-growing tumor cells.
Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Marín-Hernández A; Ruiz-Azuara L; Moreno-Sánchez R
Toxicol Appl Pharmacol; 2006 Sep; 215(2):208-17. PubMed ID: 16580038
[TBL] [Abstract][Full Text] [Related]
13. Mitochondria, hexokinase and pyruvate kinase isozymes in the aerobic glycolysis of tumor cells.
Petrucci D; Cesare P; Colafarina S
Ital J Biochem; 1997 Sep; 46(3):131-41. PubMed ID: 9442422
[TBL] [Abstract][Full Text] [Related]
14. Effect of the antitumor drug lonidamine on glucose metabolism of adriamycin-sensitive and -resistant human breast cancer cells.
Fanciulli M; Valentini A; Bruno T; Citro G; Zupi G; Floridi A
Oncol Res; 1996; 8(3):111-20. PubMed ID: 8823807
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate.
Pereira da Silva AP; El-Bacha T; Kyaw N; dos Santos RS; da-Silva WS; Almeida FC; Da Poian AT; Galina A
Biochem J; 2009 Feb; 417(3):717-26. PubMed ID: 18945211
[TBL] [Abstract][Full Text] [Related]
16. Casiopeina II-gly and bromo-pyruvate inhibition of tumor hexokinase, glycolysis, and oxidative phosphorylation.
Marín-Hernández A; Gallardo-Pérez JC; López-Ramírez SY; García-García JD; Rodríguez-Zavala JS; Ruiz-Ramírez L; Gracia-Mora I; Zentella-Dehesa A; Sosa-Garrocho M; Macías-Silva M; Moreno-Sánchez R; Rodríguez-Enríquez S
Arch Toxicol; 2012 May; 86(5):753-66. PubMed ID: 22349057
[TBL] [Abstract][Full Text] [Related]
17. Glycolytic, glutaminolytic and pentose-phosphate pathways in promyelocytic HL60 and DMSO-differentiated HL60 cells.
Ahmed N; Williams JF; Weidemann MJ
Biochem Mol Biol Int; 1993 Apr; 29(6):1055-67. PubMed ID: 8330014
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".
Lampidis TJ; Kurtoglu M; Maher JC; Liu H; Krishan A; Sheft V; Szymanski S; Fokt I; Rudnicki WR; Ginalski K; Lesyng B; Priebe W
Cancer Chemother Pharmacol; 2006 Dec; 58(6):725-34. PubMed ID: 16555088
[TBL] [Abstract][Full Text] [Related]
19. Ifosfamide metabolites CAA, 4-OH-Ifo and Ifo-mustard reduce apical phosphate transport by changing NaPi-IIa in OK cells.
Patzer L; Hernando N; Ziegler U; Beck-Schimmer B; Biber J; Murer H
Kidney Int; 2006 Nov; 70(10):1725-34. PubMed ID: 17003823
[TBL] [Abstract][Full Text] [Related]
20. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase.
Marín-Hernández A; Rodríguez-Enríquez S; Vital-González PA; Flores-Rodríguez FL; Macías-Silva M; Sosa-Garrocho M; Moreno-Sánchez R
FEBS J; 2006 May; 273(9):1975-88. PubMed ID: 16640561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
